MedTrace Logo

Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

NCT05616598 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-02-08

No results posted yet for this study

Summary

Hepatitis C virus is commona viral infection. Direct-acting antiviral (DAA) oral drugs has been used in treatment of HCVs. the effect of these drugs on male infertility is still under investigation.

Conditions

  • Male Infertility
  • HCV

Interventions

DRUG

Sofosbuvir +daclatasvir+ simeprevir+Ribavirin

Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months

Sponsors & Collaborators

  • Benha University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-11-25
Completion
2022-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05616598 on ClinicalTrials.gov